Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Russell Lafrance

Orthopaedic Surgery Hamilton, NY Medical Doctor

NPI 1245356187 CMS profile 853970

85 College St, Hamilton, NY 13346

Open in the dashboard

General payments

$12,794

99 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Russell Lafrance of Hamilton, NY is reported in the CMS Open Payments database as having received $12,794 across 99 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $822 11
2024 General $269 10
2022 General $106 5
2021 General $6,695 24
2020 General $2,221 17
2019 General $2,682 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Russell Lafrance
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Russell Lafrance were reported at $822. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Russell Lafrance Orthopaedic Surgery median Middle half National median
2019 $2,682 $644 $140–$2,844 $163
2020 $2,221 $312 $75–$1,860 $114
2021 $6,695 $520 $117–$2,495 $132
2022 $106 $598 $128–$2,731 $149
2023 $0 $461 $128–$2,264 $160
2024 $269 $497 $134–$2,475 $164
2025 $822 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $4,825 43 payments
  2. Arthrex, Inc. $4,487 6 payments
  3. Prodigy Surgical Distribution, Inc. $2,400 2 payments
  4. Horizon Therapeutics plc $233 19 payments
  5. Medacta USA, Inc. $224 3 payments
  6. DePuy Synthes Sales Inc. $202 8 payments
  7. Intrinsic Therapeutics $174 5 payments
  8. Zimmer Biomet Holdings, Inc. $83 2 payments
  9. Fidia Pharma USA Inc. $44 3 payments
  10. Vertex Pharmaceuticals Incorporated $43 2 payments
  11. Other $79 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $7,677 6 payments
  2. Education $2,400 2 payments
  3. Food and Beverage $2,028 88 payments
  4. Travel and Lodging $689 3 payments
Products named General payments · program years 2019–2025
  1. BIORAPTOR $2,211 6 payments
  2. HEALICOIL $1,690 2 payments
  3. Q-FIX Sports Med Shoulder $1,678 2 payments
  4. Fast-Fix 360 $1,660 1 payment
  5. OSTEORAPTOR $1,660 1 payment
  6. Q-FIX Hip $1,621 2 payments
  7. Q-FIX Extremities & Limb Restoration $1,605 2 payments
  8. ACCUPASS DIRECT Crescent XL $1,600 1 payment
  9. SPEEDLOCK Hip $1,600 1 payment
  10. BIORAPTOR Knotless $1,600 1 payment
  11. Other $3,347 103 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 62 billing codes

Paid by Medicare

$64,278

Of which drugs: $132

Medicare patients

308

Average age 70

Services billed

2,257

164 women, 144 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 58%
Diabetes 26%
Ischemic heart disease 20%
COPD 16%
Chronic kidney disease 14%
Atrial fibrillation 13%
Depression 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 107 1,508 $132

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

99 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record